Arcturus Therapeutics LTD. – Ordinary Shares (NASDAQ:ARCT) Sellers Decreased By 3.63% Their Shorts

May 16, 2018 - By Patrick Harkless

Arcturus Therapeutics LTD. – Ordinary Shares (NASDAQ:ARCT) noted a decrease of 3.63% in shares shorted. FINRA published shares shorted of ARCT’s total 87,600 shares. That’s 3.63% down from 90,900 shares. Former ARCT’s position will need 3 days to restore. It has 29,200 average volume.

Ticker’s shares touched $5.93 during the last trading session after 4.22% change.Currently Arcturus Therapeutics Ltd. is downtrending after 30.95% change in last May 16, 2017. ARCT has 18,450 shares volume. The stock underperformed the S&P 500 by 42.50%.

Arcturus Therapeutics Ltd. operates as an RNA medicines company.The company has $ market cap. The Company’s RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.Currently it has negative earnings. The firm owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 patents and patent applications issued in the United States, Europe, Japan, China, and other countries.

For more Arcturus Therapeutics Ltd. (NASDAQ:ARCT) news released recently go to:,,, or The titles are as follows: “Arcturus Therapeutics Founder Joseph Payne Dismisses Board’s Baseless Lawsuit as Desperate Entrenchment Tactic” released on April 23, 2018, “Arcturus Therapeutics Founder Joseph Payne Successfully Prevents Board’s Egregious Attempt to Dilute Shareholders” on May 02, 2018, “Arcturus Therapeutics Founder Joseph Payne Welcomes Court Decision to Set Date and Agenda of Extraordinary …” with a publish date: May 14, 2018, “Arcturus Therapeutics Files Lawsuit Against Joseph E. Payne and His Associates for Violations of Federal Securities …” and the last “Arcturus Therapeutics Files Form 20-F” with publication date: May 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: